Program
neladalkib
In GlaxoSmithKline's pipeline, Brain-penetrant anaplastic lymphoma kinase (ALK)-selective tyrosine kinase inhibitor (TKI)
. Its studies are mostly in Neoplasm Metastasis · Carcinoma, Non-Small-Cell Lung, led by GlaxoSmithKline.
Furthest: phase 3, since Nov 8, 20242 company-led studies, 2 open or runningNext primary completion: Dec 2027 (phase 2)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| GlaxoSmithKline | 22 open or running | phase 3since Nov 8, 2024 | May 17, 2022 | Dec 2027phase 2 · NCT05384626 |
- Named in GlaxoSmithKline’s own pipeline as
neladalkib GSK6739060
, phase 4, as of Sep 30, 2026 (source).
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- May 17, 2022First study: phase 2 study in Neoplasm MetastasisFirst studyNCT05384626 · 840 planned · United States, Australia, Belgium and more
- Nov 8, 2024Phase 3 study in Carcinoma, Non-Small-Cell LungNCT06765109 · 450 planned · United States, Argentina, Australia and more
Ahead
- Dec 2027Primary completion: phase 2 study in Neoplasm MetastasisNCT05384626
- Dec 2029Primary completion: phase 3 study in Carcinoma, Non-Small-Cell LungNCT06765109
TargetBeta
“Brain-penetrant anaplastic lymphoma kinase (ALK)-selective tyrosine kinase inhibitor (TKI)”the company's pipeline, read by Claude · source
Other programs on ALK
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| Crizotinibrule | Pfizer | phase 4 | 31 |
| lorlatinibrule | Pfizer | phase 4 | 20 |
| gilteritinibrule | Astellas Pharma | phase 3 | 20 |
| ensartinibrule | Betta Pharmaceuticals | phase 3 | 12 |
| repotrectinibrule | Bristol-Myers Squibb | phase 3 | 9 |
| Foritinib Succinate | Fosun Pharma | phase 2 | 1 |
| ALK Molecular Glue Degrader TRI-611rule | triana-biomedicines-inc | phase 2 | 1 |
| AQUA07 | Hoffmann-La Roche | phase 1 | 1 |
| SIM0518rule | Simcere Pharmaceutical Group | phase 1 | 1 |
Studies
All 2 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT06765109Carcinoma, Non-Small-Cell Lung · United States, Argentina, Australia and more | 3 | Recruiting | Dec 2029 | 450 |
| NCT05384626Neoplasm Metastasis · United States, Australia, Belgium and more | 2 | Recruiting | Dec 2027 | 840 |
How it is read
Names in the registry
- “Neladalkib (NVL-655)”, 2 entries
Conditions, from the studies’ own filings
- Neoplasm Metastasis, 1 study
- Carcinoma, Non-Small-Cell Lung, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.